This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.
Eli Lilly and Company (NYSE: LLY) can become the first biopharma company to reach the $1 trillion valuation threshold, courtesy of an under-trial orally administered GLP-1 drug, Orforglipron, as per the latest investment note from Morgan Stanley.
Related Story Eli Lilly and Company’s Tirzepatide GLP-1 Agonist For Weight Loss Reverses Fatty Liver Disease in a “Clinically Meaningful” Way
To wit, Morgan Stanley's Terence Flynn sees Orforglipron's phase three trial results, due in 2025, as a key catalyst for Eli Lilly and Company, paving the way for the high-flying pharmaceutical stock to potentially reach a $1 trillion valuation. Accordingly, the Wall Street giant has now pegged a street-high stock price target of $950 per share for Eli Lilly, corresponding to an upside potential of over 23 percent.
Glucagon-Like Peptide-1 (GLP-1) hormone helps suppress hunger in a number of ways, including by stimulating the release of insulin in the pancreas, blocking the unhelpful release of glucagon after meals to prevent excess glucose from entering the bloodstream, and slowing gastric emptying to reduce the overall intake of food.
Eli Lilly and Company currently offers the injectable Tirzepatide as one of its proprietary drugs to combat diabetes and obesity, leveraging both GLP-1 and Glucose-dependent Insulinotropic Polypeptide (GIP) agonists to offer better efficacy. Eli Lilly markets Tirzepatide under the Mounjaro and Zepbound labels, with the former geared toward diabetes and the latter billed as a treatment for obesity.
Nonetheless, orally administered GLP-1 drugs are currently considered the holy grail in pharmaceutically-induced weight loss. As per the results of Orforglipron's phase two trial data, study participants were able to achieve an average weight loss of between 8.6 percent and 12.6 percent at 26 weeks of treatment.
We recently reported on the positive effect that Eli Lilly and Company's Tirzepatide GLP-1 agonist produced in countering the fatty liver disease Metabolic dysfunction-Associated Steatohepatitis (MASH).
While announcing its earnings for the fourth quarter of 2023, Eli Lilly and Company disclosed that it beat consensus revenue expectations of $8.95 billion for the quarter by reporting actual revenue of $9.35 billion, with Mounjaro's quarterly sales increasing to $2.21 billion vs. the $1.75 billion consensus estimate. The drug maker now expects to earn between $40.4 billion and $41.6 billion in full-year revenue.
The website gametalkz.com is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
A few years ago, MediaTek garnered its popularity through its Helio lineup of chipsets that were found in mid-range and affordable smartphones. The Taiwanese firm had cemented its position firmly in this category, but it was believed that the company could not match the likes of Qualcomm in the flagship silicon space.
Warner Bros. is shifting their focus away from a “volatile” AAA console market and toward mobile and free-to-play gaming, after the troubled development and underwhelming launch of Suicide Squad: Kill the Justice League.
Warner Bros. Discovery gaming boss J.B. Perrette has said that the company will focus on its biggest franchises moving forward, as well as live service, free-to-play titles, and mobile games.
Warner Bros Discovery’s CEO and President of Global Streaming and Games just openly spoke about making new live service games out of franchises like Harry Potter.
Entertainment giant Warner Bros is still planning on focusing on live-service titles in spite of a lacklustre reception to Suicide Squad Kill the Justice League.
Warner Bros. is shifting their focus away from a “volatile” AAA console market and toward mobile and free-to-play gaming, after the troubled development and underwhelming launch of Suicide Squad: Kill the Justice League.
Warner Bros. Games remains undeterred by the sub-par critical and commercial performance of Suicide Squad: Kill the Justice League and plans to further lean into the live service model for its games going forward. J.B. Perrette, CEO and President, Global Streaming and Games at Warner Bros. Discovery, laid out the company's games strategy at a recent Morgan Stanley speaking event, reiterating the studio's intentions to invest more in 'games as a service' model, free-to-play games and mobile titles, and expressing doubts about the “volatile” business of bespoke triple-A games on consoles.
Despite dealing with the various layoffs and game cancellations, there is no shortage of games released into the marketplace. It’s been a rough couple of years for the video game industry post-pandemic. But that hasn’t stopped some companies from pivoting towards a new means of boosting revenue. Warner Bros. is one company that is looking to make some changes to the kinds of games it develops.